Asset profile

AZD4604

Unknown / undisclosed

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Partialdesign only

Evidence outlook · results not reported

AJAX (NCT06020014) · Asthma

The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.

AJAX (NCT06020014): The study was randomized, quadruple-blind, and placebo-controlled, with 339 participants enrolled. Its primary endpoint was time to the first CompEx Asthma event, a composite surrogate measure, and results are not posted, so whether the primary comparison was met or missed is unknown.

How the evidence outlook works ↗

Competitive landscape

70 competitors in this universe: 1 direct rival (same mechanism and indication), 9 same-class, 60 same-indication; 66 further along in development.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
AZD4604: this drugPhase 2—JAK1
AZD0449Phase 1—JAK1
Abrocitinib (Cibinqo)ApprovedSmall moleculeJAK1
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1
LNK01001Phase 3Small moleculeJAK1
LW402Phase 3Small moleculeJAK1
VC005Phase 3Small moleculeJAK1, JAK1
GSK2586184Phase 2Small moleculeJAK1, JAK1
IN-115314Phase 2Small moleculeJAK1
JYP0061Phase 2Small moleculeJAK1
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptor
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor
Albuterol HFA (Armstrong's)ApprovedSmall moleculeBeta-2 adrenergic receptor
Albuterol HFA (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptor
Albuterol Sulfate (Armstrong)ApprovedSmall moleculeBeta-2 adrenergic receptor

…and 55 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Compare head-to-head

Upcoming events

No upcoming readouts on record for this asset.

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 2 (2)
Phase 1 (4)